{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:24:21Z","timestamp":1761110661857,"version":"3.40.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:p>The aim is to investigate the usefulness of <jats:sup>177<\/jats:sup>Lu-DOTA-0-Tyr3-Octreotate (DOTATATE) healthy organs\u2019 (spleen, kidneys, bone marrow) standard uptake value for the prediction of subacute hematological toxicity in patients undergoing <jats:sup>177<\/jats:sup>Lu-DOTATATE treatment. All patients referred from January 2021 to May 2022 for <jats:sup>177<\/jats:sup>Lu-DOTATATE treatment were retrospectively screened. For each treatment session, baseline clinical data including age, sex, weight, delay between <jats:sup>177<\/jats:sup>Lu-DOTATATE treatment and last cold somatostatin analogue intake were collected. Mean standardized uptake value (SUVmean) of healthy organs was measured and analyzed by generalized linear mixed effect models. Outcomes (significant decrease of platelets, hemoglobin levels and neutrophils) were assessed 1 month later, considering their within-subject biological coefficient of variation, published by the European Federation of Clinical Chemistry and Laboratory Medicine. A total of 9 patients (33 treatment sessions) were included. No predictive factors were identified for platelet and neutrophil decrease. Splenic SUVmean was found to be a significant predictor of hemoglobin levels decrease. Using an optimal threshold of\u2005\u22656.22, derived sensitivity and specificity to predict hemoglobin decrease were 85.7% [46.4; 99.0] and 76.9% [57.5; 89.2] respectively with an accuracy of 82.4%. Although not significantly predictive of hematological toxicity, bone marrow SUVmean and renal SUVmean were correlated with splenic SUVmean. Quantitative single photon emission computed tomography and healthy organs analysis might help to foresee hematological subacute toxicity in patients undergoing <jats:sup>177<\/jats:sup>Lu-DOTATATE treatment and improve patient management.<\/jats:p>","DOI":"10.1097\/md.0000000000032212","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:28:09Z","timestamp":1673558889000},"page":"e32212","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Predicting subacute hematological toxicity of 177Lu-DOTATATE therapy using healthy organs\u2019 uptake on post-treatment quantitative SPECT: A pilot study"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-4841","authenticated-orcid":false,"given":"David","family":"Morland","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"},{"name":"Laboratoire de Biophysique, UFR de M\u00e9decine, Universit\u00e9 de Reims Champagne-Ardenne, Reims, France"},{"name":"CReSTIC (Centre de Recherche en Sciences et Technologies de l\u2019Information et de la Communication), EA 3804, Universit\u00e9 de Reims Champagne-Ardenne, Reims, France"},{"name":"Unit\u00e0 di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Katherine Anna","family":"Triumbari","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hoog","sequence":"additional","affiliation":[{"name":"Service de Radiophysique et Radioprotection, Institut Godinot, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghali","family":"S\u00e9zin","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Dejust","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[{"name":"H\u00e9patogastroent\u00e9rologie, Universit\u00e9 de Reims Champagne-Ardenne and H\u00f4pital Robert Debr\u00e9, CHU de Reims, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Paris","sequence":"additional","affiliation":[{"name":"Radiopharmacie, Institut Godinot, Reims, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Papathanassiou","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"},{"name":"Laboratoire de Biophysique, UFR de M\u00e9decine, Universit\u00e9 de Reims Champagne-Ardenne, Reims, France"},{"name":"CReSTIC (Centre de Recherche en Sciences et Technologies de l\u2019Information et de la Communication), EA 3804, Universit\u00e9 de Reims Champagne-Ardenne, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejmp.2022.03.011","article-title":"Proof-of-concept of DosiTest: a virtual multicentric clinical trial for assessing uncertainties in molecular radiotherapy dosimetry","volume":"97","author":"Kayal","year":"2022","journal-title":"Phys Medica"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40658-020-0278-3","article-title":"Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT\/CT systems","volume":"7","author":"Peters","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2967\/jnumed.121.262464","article-title":"A guide to combat harmonization of imaging biomarkers in multicenter studies","volume":"63","author":"Orlhac","year":"2022","journal-title":"J Nucl Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10408363.2016.1150252","article-title":"Generation of data on within-subject biological variation in laboratory medicine: an update","volume":"53","author":"Braga","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/RLU.0000000000003412","article-title":"Clinical assessment of 177Lu-DOTATATE quantification by comparison of SUV-based parameters measured on both post-PRRT SPECT\/CT and 68Ga-DOTATOC PET\/CT in patients with neuroendocrine tumors: a feasibility study","volume":"46","author":"Thuillier","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm11040919","article-title":"Early complications of radioisotope therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasms-a preliminary study","volume":"11","author":"Bober","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.mednuc.2007.03.003","article-title":"Les limites du SUV","volume":"31","author":"Buvat","year":"2007","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.117.192203","article-title":"Long-acting somatostatin analog therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions","volume":"59","author":"Ayati","year":"2018","journal-title":"J Nucl Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5603\/NMR.a2018.0012","article-title":"Significance of splenic uptake on somatostatin receptor imaging studies","volume":"21","author":"Sarikaya","year":"2018","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1002\/cam4.4131","article-title":"Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13014-017-0824-x","article-title":"Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma","volume":"12","author":"Liu","year":"2017","journal-title":"Radiat Oncol"},{"key":"R16-20250504","first-page":"1124","article-title":"Tumor sink effect: myth or reality?","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy","volume":"39","author":"Beauregard","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1038\/s41598-020-66110-w","article-title":"Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies","volume":"10","author":"Da-Ano","year":"2020","journal-title":"Sci Rep"},{"key":"R19-20250504","first-page":"189","article-title":"Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: a decade of experience","volume":"31","author":"Kesavan","year":"2016","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:49:21Z","timestamp":1746334161000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":17,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032212","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}